Aisling Capital Management LP Long-Term Concentrated

CIK: 0001766721 · Show all filings

Period: Q2 2022 (← Previous) (Next →)

Filing Date: Aug 10, 2022

Total Value ($000): $140,160 (100.0% shares, 0.0% debt)

Holdings (19)

BBIO BridgeBio Pharma Inc. (BBIO) 39.3%
Value ($000) $55,099 Shares 6,068,125 Est. Cost $40.43 Unrealized -79.3%
SNDX Syndax Pharmaceuticals, Inc. (SNDX) 14.1%
Value ($000) $19,721 Shares 1,025,000 Est. Cost $10.24 Unrealized +62.7%
GLUE Monte Rosa Therapeutics Inc. (GLUE) 10.2%
Value ($000) $14,237 Shares 1,472,331 Est. Cost $20.37 Unrealized -50.7%
BMEA Biomea Fusion Inc. (BMEA) 6.8%
Value ($000) $9,569 Shares 798,757 Est. Cost $17.65 Unrealized -66.8%
ACRS Aclaris Theraputics Inc. (ACRS) 6.3%
Value ($000) $8,857 Shares 634,455 Est. Cost $10.31 Unrealized +36.0%
NUVB Nuvation Bio Inc. (NUVB) 5.9%
Value ($000) $8,233 Shares 2,541,009 Est. Cost $11.18 Unrealized -61.0%
Verona Pharma plc (VRNA) 4.0%
Value ($000) $5,583 Shares 1,332,485 Est. Cost $7.38 Unrealized
Elevation Oncology Inc. (ELEV) 2.8%
Value ($000) $3,969 Shares 2,834,910 Est. Cost $13.57 Unrealized
Talaris Therapeutics Inc. (TALS) 2.2%
Value ($000) $3,080 Shares 682,923 Est. Cost $14.69 Unrealized
Poseida Therapeutics Inc. (PSTX) 1.9%
Value ($000) $2,692 Shares 1,043,267 Est. Cost $8.87 Unrealized
Reneo Pharmaceuticals Inc. (RPHM) 1.7%
Value ($000) $2,348 Shares 886,075 Est. Cost $9.33 Unrealized
Spruce Biosciences, Inc. (SPRB) 1.5%
Value ($000) $2,098 Shares 1,205,511 Est. Cost $24.31 Unrealized
Viracta Therapeutics Inc. (VIRX) 0.8%
Value ($000) $1,120 Shares 288,571 Est. Cost $11.34 Unrealized
Marker Therapeutics, Inc. (MRKR) 0.7%
Value ($000) $1,037 Shares 3,142,857 Est. Cost $4.35 Unrealized
AVROBIO, Inc. (AVRO) 0.7%
Value ($000) $929 Shares 1,009,779 Est. Cost $16.72 Unrealized
Aeglea Biotherapeutics Inc. (AGLE) 0.6%
Value ($000) $854 Shares 1,691,151 Est. Cost $8.00 Unrealized
Atreca Inc. (BCEL) 0.5%
Value ($000) $694 Shares 387,653 Est. Cost $18.84 Unrealized
Zosano Pharma Corporation (ZSAN) 0.0%
Value ($000) $24 Shares 77,663 Est. Cost $2.15 Unrealized
Nabriva Therapeutics plc (NBRV) 0.0%
Value ($000) $16 Shares 90,000 Est. Cost $1.66 Unrealized